Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 353

1.

Nearly a third of abnormalities found after first-trimester screening are different than expected: 10-year experience from a single center.

Alamillo CM, Krantz D, Evans M, Fiddler M, Pergament E.

Prenat Diagn. 2013 Mar;33(3):251-6. doi: 10.1002/pd.4054. Epub 2013 Jan 27.

PMID:
23354915
2.

Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities.

Zimmermann R, Hucha A, Savoldelli G, Binkert F, Achermann J, Grudzinskas JG.

Br J Obstet Gynaecol. 1996 Oct;103(10):1009-14.

PMID:
8863700
3.

Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13.

Santorum M, Wright D, Syngelaki A, Karagioti N, Nicolaides KH.

Ultrasound Obstet Gynecol. 2017 Jun;49(6):714-720. doi: 10.1002/uog.17283. Epub 2017 Apr 26.

PMID:
27549925
4.

Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.

Kagan KO, Anderson JM, Anwandter G, Neksasova K, Nicolaides KH.

Prenat Diagn. 2008 Dec;28(13):1209-13. doi: 10.1002/pd.2149.

PMID:
19039823
5.

Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy.

Brizot ML, Snijders RJ, Butler J, Bersinger NA, Nicolaides KH.

Br J Obstet Gynaecol. 1995 Feb;102(2):127-32. Review.

PMID:
7538782
6.

If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.

Marsk A, Grunewald C, Saltvedt S, Valentin L, Almström H.

Acta Obstet Gynecol Scand. 2006;85(5):534-8.

PMID:
16752230
7.

Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.

Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH.

Ultrasound Obstet Gynecol. 2008 Sep;32(4):488-92. doi: 10.1002/uog.6123.

9.

First trimester screening for other trisomies than trisomy 21, 18, and 13.

Tørring N, Petersen OB, Becher N, Vogel I, Uldbjerg N; Danish Fetal Medicine Study Group; Danish Clinical Genetics Study Group.

Prenat Diagn. 2015 Jun;35(6):612-9. doi: 10.1002/pd.4584. Epub 2015 Apr 9.

PMID:
25708180
10.

Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test.

Gil MM, Revello R, Poon LC, Akolekar R, Nicolaides KH.

Ultrasound Obstet Gynecol. 2016 Jan;47(1):45-52. doi: 10.1002/uog.15783. Epub 2015 Oct 26.

11.

Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.

Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH.

Hum Reprod. 2008 Sep;23(9):1968-75. doi: 10.1093/humrep/den224. Epub 2008 Jun 10.

PMID:
18544579
12.

Analysis of the impact of PAPP-A, free β-hCG and nuchal translucency thickness on the advanced first trimester screening.

Berktold L, von Kaisenberg CS, Hillemanns P, Vaske B, Schmidt P.

Arch Gynecol Obstet. 2013 Mar;287(3):413-20. doi: 10.1007/s00404-012-2585-y. Epub 2012 Oct 19. Erratum in: Arch Gynecol Obstet. 2013 Aug;288(2):467. V Kaisenberg, C [corrected to von Kaisenberg, C S].

PMID:
23080546
13.

[Results of prenatal screening for fetal chromosome abnormality during the first trimester pregnancy in Guangzhou].

Xu Z, Li B, Liao C, Sun Q, Bai X, Li D.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2014 Oct;31(5):632-5. doi: 10.3760/cma.j.issn.1003-9406.2014.01.021. Chinese.

PMID:
25297598
14.

Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.

Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH.

Ultrasound Obstet Gynecol. 2006 Feb;27(2):151-5.

15.

First-trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free β-hCG and PAPP-A: a 5-year prospective study.

Ghaffari SR, Tahmasebpour AR, Jamal A, Hantoushzadeh S, Eslamian L, Marsoosi V, Fattahi F, Rajaei M, Niroomanesh S, Borna S, Beigi A, Khazardoost S, Saleh-Gargari S, Rahimi-Sharbaf F, Farrokhi B, Bayani N, Tehrani SE, Shahsavan K, Farzan S, Moossavi S, Ramezanzadeh F, Dastan J, Rafati M.

Ultrasound Obstet Gynecol. 2012 May;39(5):528-34. doi: 10.1002/uog.10051.

16.

Improved diagnostic accuracy by using secondary ultrasound markers in the first-trimester screening for trisomies 21, 18 and 13 and Turner syndrome.

Karadzov-Orlic N, Egic A, Milovanovic Z, Marinkovic M, Damnjanovic-Pazin B, Lukic R, Joksic I, Curkovic A, Mikovic Z.

Prenat Diagn. 2012 Jul;32(7):638-43. doi: 10.1002/pd.3873. Epub 2012 May 9.

PMID:
22570267
17.

First trimester predictors of adverse pregnancy outcomes.

Brameld KJ, Dickinson JE, O'Leary P, Bower C, Goldblatt J, Hewitt B, Murch A, Stock R.

Aust N Z J Obstet Gynaecol. 2008 Dec;48(6):529-35. doi: 10.1111/j.1479-828X.2008.00912.x.

PMID:
19133038
18.

Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies.

Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH.

Ultrasound Obstet Gynecol. 2013 Jul;42(1):34-40. doi: 10.1002/uog.12504. Epub 2013 Jun 7.

19.

First-trimester screening for trisomy 21 in Denmark: implications for detection and birth rates of trisomy 18 and trisomy 13.

Ekelund CK, Petersen OB, Skibsted L, Kjaergaard S, Vogel I, Tabor A; Danish Fetal Medicine Research Group.

Ultrasound Obstet Gynecol. 2011 Aug;38(2):140-4. doi: 10.1002/uog.8929.

20.

First-trimester risk calculation for trisomy 13, 18, and 21: comparison of the screening efficiency between 2 locally developed programs and commercial software.

Sørensen S, Momsen G, Sundberg K, Friis-Hansen L, Jørgensen FS.

Clin Chem. 2011 Jul;57(7):1023-31. doi: 10.1373/clinchem.2010.161299. Epub 2011 May 16.

Supplemental Content

Support Center